
    
      STUDY DESIGN

        -  Multi-center, retrospective cohort chart review study design

        -  Data will be collected on all triple therapy recipients who were discharged from a
           Methodist Health System (MHS) facility with prescriptions for a combination of aspirin,
           P2Y12 Inhibitor and an OAC of either a NOAC or warfarin between April 1, 2017 - April 1,
           2018

        -  Patient list will be generated in EPIC

        -  All data will be obtained from EPIC

        -  All data will be collected retrospectively after the patient is discharged from the
           hospital

        -  Data collection (planned completion date): May 2019

      Study Inclusion Criteria:

        -  18 years or older

        -  AF diagnosis

        -  ICD10 for ACS, STEMI or NSTEMI

        -  Discharged with triple therapy agents of aspirin, P2Y12 inhibitor (clopidogrel,
           prasugrel, or ticagrelor), and OAC (warfarin, edoxaban, dabigatran, rivaroxaban, or
           apixaban) status post-stent

      Study Exclusion Criteria:

        -  Patients less than 18 years of age

        -  Prior intracranial bleeding prior to study start date

        -  GI hemorrhage within 1 month prior to study start date

        -  Major bleeding event with 1 month prior to study start date

        -  Hemorrhage disorder

        -  Stroke within 1 month prior to study start date

        -  Cardiogenic shock during admission at start date

        -  Contraindication to use of the study medications

        -  Peptic ulcer in the prior 6 months prior to study start date

        -  Thrombocytopenia (platelet concentration lower than 50Ã—109/L)

        -  Thrombolysis In Myocardial Infarction (TIMI) major bleeding in the prior 12 months of
           study start date

        -  Pregnancy

        -  History of DVT or PE currently on OAC
    
  